CACNA1G

Voltage-dependent T-type calcium channel subunit alpha-1G

Score: 0.698 Price: $0.70 High Druggability Status: active Wiki: CACNA1G

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

31

KG EDGES

25

DEBATES

1

3D Protein Structure

🧬 CACNA1G — PDB 6KZO Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

High

Score: 0.90

Clinical Stage

Approved

Target Class

Ion Channel

Safety

0.60

Druggability Analysis

Drug Development0.75

Structural Tractability0.70

Target Class0.85

Safety Profile0.60

Key Metrics

PDB Structures:

2

Known Drugs:

2

Approved:

1

In Clinical Trials:

0

Drug Pipeline (2 compounds)

1 Approved

Druggability Rationale: CACNA1G exhibits high druggability (0.90 score) due to its well-defined ion channel architecture, availability of high-resolution structural data (3.1 Å cryo-EM), and validated clinical precedent with approved (ethosuximide) and withdrawn (mibefradil) drugs. The deep hydrophobic binding pocket characteristic of voltage-gated calcium channels provides an excellent substrate for small molecule inhibitors with favorable ligand binding kinetics.

Mechanism: Small molecule blocker of T-type calcium channel activity

Drug Pipeline (2 compounds)

1 Approved

Known Drugs:

Ethosuximide (approved) — Absence seizures

Mibefradil (withdrawn) — Hypertension

Structural Data:

PDB (2) ✓AlphaFold ✓Cryo-EM ✓

UniProt: A0A0B4J1X2

🧬 3D Protein Structure

🧬 CACNA1G — PDB 6KZO Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

T-type calcium channel selectivity is challenging due to high sequence homology among CACNA1G (Cav3.1), CACNA1H (Cav3.2), and CACNA1I (Cav3.3) isoforms; achieving isoform-specific inhibition is critical to avoid off-target cardiovascular effects observed with mibefradil. Structural divergence in the selectivity filter and S5-S6 pore regions offers opportunities for isoform-selective ligand design.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (1)

Sleep Spindle-Synaptic Plasticity Enhancement0.721

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (1)

CACNA1G→neurodegeneration

co discussed (12)

BMAL1→CACNA1GHCRTR2→CACNA1GCLOCK→CACNA1GBDNF→CACNA1GAQP4→CACNA1G

▸ Show 7 more

MTNR1A→CACNA1GCX3CR1→CACNA1GHCRT→CACNA1GCACNA1G→ADORA2ACACNA1G→ADRA2ACACNA1G→HCRTCACNA1G→AQP4

implicated in (1)

CACNA1G→neurodegeneration

inhibits (1)

Nnc-55-0396→CACNA1G

mediates (1)

CACNA1G→Amyloid Beta Production

participates in (1)

CACNA1G→Synaptic function / plasticity

protects against (1)

CACNA1G→Pro-amyloidogenic Environment

regulates (1)

CACNA1G→Calcium Homeostasis

targets (1)

h-8d270062→CACNA1G

Debate History (1)

Should CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) be pr2026-04-21